On February 21, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, along with other business highlights. The announcement included the approval of CASGEVY™ in multiple regions for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), and the progress of clinical trials for several product candidates, including CTX112™ and CTX131™ targeting CD19 and CD70, and in vivo gene editing candidates CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a). The company also reported on the ongoing clinical trial for CTX211™ for Type 1 Diabetes (T1D) treatment. CRISPR Therapeutics strengthened its balance sheet with a $280 million registered direct offering, bringing its current cash position to over $2.1 billion. The financial results showed a net income of $89.3 million for the fourth quarter of 2023, compared...Show More

On February 21, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, along with other business highlights. The announcement included the approval of CASGEVY™ in multiple regions for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), and the progress of clinical trials for several product candidates, including CTX112™ and CTX131™ targeting CD19 and CD70, and in vivo gene editing candidates CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a). The company also reported on the ongoing clinical trial for CTX211™ for Type 1 Diabetes (T1D) treatment. CRISPR Therapeutics strengthened its balance sheet with a $280 million registered direct offering, bringing its current cash position to over $2.1 billion. The financial results showed a net income of $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the same period in 2022. Cash, cash equivalents, and marketable securities were reported at $1,695.7 million as of December 31, 2023. The company's CEO, Samarth Kulkarni, Ph.D., expressed excitement for the upcoming year with a focus on continuing to innovate and execute clinical trials across various therapeutic areas.